You are here

P&T® Journal contents for April 2005

Features

Editorial Board Spotlight
Ramblin’ Ransom: Reviewer, Writer, and Researcher
P&T’s Seattle-based neurologist, Bruce R. Ransom, is savvy, slightly sardonic, and—oh yes—smart.
Sonja Sherritze
Letter to the Editor
Triptan Use in the Real World
The use of the two-hour efficacy time point in evaluating triptans is debated.
Richard White, PhD, MPH
Meeting Highlights
54th Scientific Session, American College of Cardiology
Lawrence and Sharon Prescott review some new therapies for atherosclerosis, coronary artery disease, hypertension, myocardial infarction, acute coronary syndrome, stroke, and heart failure
Lawrence M. Prescott, PhD, and Sharon L. Prescott
Agalsidase beta: Enzyme Replacement Therapy for Fabry Disease
The authors discuss a recombinant product (Fabrazyme®) for the treatment of a rare disorder caused by an enzyme deficiency.
Julie A. Aaron, PharmD, and Nicole T. Ansani, PharmD
Pharmaceutical-Approval Update: Oncology April 2005
The author discusses recent FDA approvals for doxorubicin HCl liposome injection (Doxil®) for patients with ovarian cancer, paclitaxel protein-bound particles for injectable suspension (Abraxane™) for the treatment of breast cancer, and erlotinib (Tarceva®) therapy for patients with non–small cell lung cancer.
Marvin M. Goldenberg, PhD, RPh, MS
Continuing Education Credit
Movement Disorders: Overview and Treatment Options
The authors review therapies for essential tremor, Parkinson’s disease, dystonia, myoclonus, chorea, tic disorders, tardive dyskinesia and akasthisia, restless limbs syndrome, and Wilson’s disease.
Ali Samii, MD, and Bruce R. Ransom, MD, PhD

Departments

Editorial
Give PEACE a Chance
David Nash, MD, MBA, discusses PEACE, a P&T subcommittee set up to contain formulary costs.
David Nash, MD, MBA
Medication Errors
Erroneous Dosing of Oral Methotrexate
Matthew Grissinger, RPh, FASCP, explains the special precautions required to avoid errors in methotrexate administration.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Ban-Busting Bill: Senate May Pass Legislation Permitting Drug Importation
Stephen Barlas discusses the factors that might lead Congress to authorize drug importation.
Stephen Barlas
Drug Forecast
Sculptra™: A Novel Treatment Approach for HIV-Associated Facial Lipoatrophy
Drs. Marzella and Antonopoulos review an injectable product, poly-l-lactic acid (Sculptra™), for patients with HIV-associated facial lipoatrophy.
Nino Marzella, BS, PharmD, and Marilena S. Antonopoulos, PharmD
New Drugs/Drug News/New Medical Devices April 2005
P&T presents the latest information about FDA approvals, drug indications, industry updates, and new devices.